The London-listed Bangladesh-based pharmaceutical company, Beximco, has had net sales in the second quarter increased 12.8% to BDT 4,359.9m / £39.0m 2016-17: £40.4m.
The company has reported profit after tax increased 12.5% to BDT 672.9m / £6.0m (2016-17: BDT 598.0m / £6.2m).
Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, said: “During the half year, we delivered strong results, maintaining excellent sales growth across our domestic and export markets. We continued to expand our portfolio with nine new product launches in the domestic market, whilst successfully shipping our second product to the US market and receiving our fourth product approval from the US FDA.
“Importantly, our oral solid dosage facility was granted WHO Prequalification, a prerequisite to participate in tenders funded by global donor agencies for certain groups of medicines. We also undertook the first acquisition in Beximco Pharma’s history, expanding and complementing our existing portfolio, which is due to complete next month. We look forward to continuing to maintain this strong financial and operational growth momentum.”